ArticleCancer reports (Hoboken, N.J.)2025
Survival Nomogram for Lung Adenocarcinoma Patients With Bone Metastasis Based on the SEER Database and an External Validation Cohort.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLung adenocarcinoma is a common type of cancer that can lead to bone metastasis and has a poor prognosis. Although previous studies have established nomograms for lung adenocarcinoma, these nomograms do not effectively predict the prognosis of lung adenocarcinoma patients with bone metastasis. This study aims to establish and validate a new nomogram to solve this problem.
methodsData were collected from the SEER database and from patients at our hospital who had been diagnosed with lung adenocarcinoma and developed bone metastases. The patients were randomly assigned into the training and internal validation sets in a 7:3 ratio. External validation was conducted using an independent patient cohort from two hospitals. Different methods were used to evaluate the nomogram's performance. The relationship between different metastatic sites and radiotherapy and chemotherapy was also analyzed to evaluate patient prognosis.
resultsThe following factors were identified as significant prognostic indicators: age, sex, marital status, T stage, N stage, tumor grade, tumor size, presence of brain and liver metastases, and receipt of chemotherapy. The nomogram's concordance indices for predicting overall survival were consistently above 0.7, and the area under the curve values, calibration plots, and decision curves all confirmed the nomogram's strong predictive accuracy. Moreover, our analysis revealed that chemotherapy was the most effective treatment modality.
conclusionsThis study developed a nomogram that can predict the prognosis of lung adenocarcinoma patients with bone metastasis. The results showed that patients with liver metastasis had the worst prognosis and that chemotherapy was the most effective treatment regimen for patients with different metastatic sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.